Applicant, as named in the Orange Book

Jazz

Jazz Pharmaceuticals plc · Nasdaq: JAZZ

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Zepzelca on 13 Dec 2029. 2 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Zepzelca NDA 213702 lurbinectedin	lurbinectedin	13 Dec 2029 patent	patent
Xywav NDA 212690 calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate	22 Feb 2041 patent, carve-out possible	patent, carve-out possible

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.